The Menarini group, grappling with the difficulties of the national market and the effects of the law in favor of generic drugs, is thinking of a pay cut in the order of 40-45% for the 1,700 scientific representatives, as an alternative to the 730 redundancies announced (reduced compared to the initial thousand).
The proposal of the Florentine company, leader in Italy in the pharmaceutical sector, 3 billion in revenues and 12,000 employees, was formalized yesterday in Rome in a meeting with trade union organizations at the Ministry of Economic Development. «We took into account the situation of the country and the problems personal and family members of our scientific representatives, many of whom have been working with the group for years», comments the general manager of the company, Domenico Simone. “Now the union negotiation phase has begun, to verify the feasibility of this road – he adds -. But it is clear that, under current conditions, there would still be a need to restructure the workforce in a consistent manner in Italy».
The instrument of the solidarity contract concerns four companies: Guidotti, Malesci and Lusofarmaco, in addition to the parent company Menarini. And it doesn't touch the productive part. “We have an investment plan for Italy which is blocked and which allocates 60 million to doubling the L'Aquila plant – explains Simone -. But to restart it, some important obstacles to the growth of the pharmaceutical industry must be removed, restoring parity between branded and generic drugs on the market".
C.Per. 01 June 2013
C.Per. – Il Sole 24 Ore – read on http://24o.it/oxmQXn
